Dashboard
Kymera Therapeutics, Inc.
KYMRNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 7Ownership changeSEC
Form 4 filing reporting change in beneficial ownership.
- Jul 2Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jul 2Ownership changeSEC
SEC Form 4 insider ownership filing.
- Jul 2Ownership changeSEC
SEC Form 4 insider ownership filing.
- Jun 30Ownership changeSEC
SEC Form 4 insider transaction filing
- Jun 30Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 30Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis updated to active, not recruiting.
- Jun 30Trial initiationClinicalTrials.gov
Phase 2 long-term extension study (NCT07677059) of KT-621 in asthma now recruiting participants.
- Jun 29Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status.
- Jun 26Ownership changeSEC
SEC Form 4 insider ownership document filed
- Jun 25Ownership changeSEC
SEC Form 4 filing for change in beneficial ownership.
- Jun 25Ownership changeSEC
SEC Form 4 filing on change in beneficial ownership.
- Jun 25OtherSEC
8-K filing (items 7.01/8.01/9.01) on 2026-06-25
- Jun 25Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 25Ownership changeSEC
SEC Form 4 filing for insider transaction.
- Jun 25Ownership changeSEC
SEC Form 4 insider ownership change filing.
- Jun 25Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 25Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 25Ownership changeSEC
Form 4 insider transaction filing.
- Jun 25Ownership changeSEC
SEC Form 4 insider ownership filing.
Not financial advice — research and opinion only. Disclosures